Compare
Two to four companies, one screen
The same numbers the feed and each dossier publish, lined up so you can weigh candidates against each other. Every figure is a public-filing estimate, identical for every subscriber, and the shaded cell in a row is simply the highest number in it — not a recommendation.
Add one more to line them up.
| Mezzion Pharma Co. Ltd OncologyPhase II Remove | |
|---|---|
| Momentum0–100 | 53 |
| Runwayestimate, months | — |
| Stage | Phase II |
| Last raiseForm D, self-reported | No Form D on file |
| Lead investigator | GOLDBERG, DANIEL E. |
| What changed | NIH R21 · $0.2M · Mechanism of neutrophil dysfunction by Plasmodium falciparum secreted histidine-rich protein IIJun 2025 · Grant renewal |
| Full dossier → |
Momentum and runway are estimates derived from public federal filings, published identically to every subscriber. This is informational only and is not investment advice. How the numbers work